Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Sumanta Kumar, Figlin, Robert A.
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902205/
https://www.ncbi.nlm.nih.gov/pubmed/20711245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902205/
https://www.ncbi.nlm.nih.gov/pubmed/20711245

Ejemplares similares